AAPL294.09+4.73 (+1.63%) ▲|ABBV250.46-1.18 (-0.47%) ▼|ABT91.99+1.25 (+1.38%) ▲|ACN133.69+9.25 (+7.43%) ▲|ADBE211.66+6.64 (+3.24%) ▲|AMAT642.79-80.22 (-11.09%) ▼|AMD550.87-30.04 (-5.17%) ▼|AMGN358.85-3.27 (-0.90%) ▼|AMT167.08+3.51 (+2.15%) ▲|AMZN244.01+5.67 (+2.38%) ▲|AVGO369.88-7.88 (-2.08%) ▼|AXP348.36+10.11 (+2.99%) ▲|BA217.42+0.95 (+0.44%) ▲|BAC58.31+1.33 (+2.33%) ▲|BKNG184.07+5.83 (+3.27%) ▲|BLK979.29+17.73 (+1.84%) ▲|BMY56.35-1.28 (-2.21%) ▼|BNY146.80+2.19 (+1.51%) ▲|BRK-B502.27+1.88 (+0.38%) ▲|C139.73-0.24 (-0.17%) ▼|CAT995.45-69.45 (-6.52%) ▼|CL92.18+0.50 (+0.55%) ▲|CMCSA24.09-0.47 (-1.89%) ▼|COF203.87+3.25 (+1.62%) ▲|COP103.55-0.41 (-0.39%) ▼|COST925.88-9.60 (-1.03%) ▼|CRM164.60+7.94 (+5.07%) ▲|CSCO116.40-1.06 (-0.90%) ▼|CVS104.62+1.17 (+1.13%) ▲|CVX166.22+0.46 (+0.28%) ▲|DE628.68-5.65 (-0.89%) ▼|DHR193.65+3.17 (+1.66%) ▲|DIS96.53+0.28 (+0.29%) ▲|DUK125.55-1.04 (-0.82%) ▼|EMR140.56-2.60 (-1.81%) ▼|FDX315.06+1.93 (+0.62%) ▲|GD362.21+7.97 (+2.25%) ▲|GE371.57-2.16 (-0.58%) ▼|GEV1,138.85-36.01 (-3.07%) ▼|GILD126.08-0.26 (-0.21%) ▼|GM75.52-1.57 (-2.03%) ▼|GOOG356.07+2.74 (+0.77%) ▲|GOOGL359.17+1.80 (+0.50%) ▲|GS1,024.54+13.17 (+1.30%) ▲|HD353.46+0.78 (+0.22%) ▲|HON220.93-2.97 (-1.33%) ▼|IBM289.18+7.97 (+2.83%) ▲|INTC128.11-11.53 (-8.25%) ▼|INTU270.19+9.19 (+3.52%) ▲|ISRG401.91+4.23 (+1.06%) ▲|JNJ252.47-1.51 (-0.59%) ▼|JPM333.67+6.34 (+1.94%) ▲|KO81.40+0.13 (+0.15%) ▲|LIN536.36+17.42 (+3.36%) ▲|LLY1,175.64-23.79 (-1.98%) ▼|LMT517.91+8.45 (+1.66%) ▲|LOW223.14+2.65 (+1.20%) ▲|LRCX386.96-46.37 (-10.70%) ▼|MA526.21+12.61 (+2.46%) ▲|MCD271.02+0.71 (+0.26%) ▲|MDLZ58.73+0.89 (+1.53%) ▲|MDT78.92+0.69 (+0.88%) ▲|META622.54+59.25 (+10.52%) ▲|MMM160.87-1.04 (-0.64%) ▼|MO72.17+0.22 (+0.30%) ▲|MRK126.10-2.41 (-1.87%) ▼|MS211.85+2.81 (+1.34%) ▲|MSFT387.67+14.65 (+3.93%) ▲|MU1,044.93-109.37 (-9.47%) ▼|NEE86.73-1.04 (-1.18%) ▼|NFLX74.01+2.61 (+3.66%) ▲|NKE42.02+0.97 (+2.35%) ▲|NOW106.39+7.11 (+7.16%) ▲|NVDA198.75-1.35 (-0.67%) ▼|ORCL143.87-2.69 (-1.83%) ▼|PEP140.59+5.19 (+3.83%) ▲|PFE23.80-0.29 (-1.18%) ▼|PG146.10-0.54 (-0.37%) ▼|PLTR127.54+10.87 (+9.32%) ▲|PM179.59-1.32 (-0.73%) ▼|QCOM183.81-0.98 (-0.53%) ▼|RTX190.13+0.40 (+0.21%) ▲|SBUX103.42+1.23 (+1.20%) ▲|SCHW95.82+3.55 (+3.84%) ▲|SO95.23-0.48 (-0.50%) ▼|SPG221.12-2.53 (-1.13%) ▼|T20.64-0.06 (-0.28%) ▼|TMO514.97+13.61 (+2.71%) ▲|TMUS173.29+5.56 (+3.31%) ▲|TSLA426.19+5.59 (+1.33%) ▲|TXN299.13+1.06 (+0.36%) ▲|UBER73.24+1.08 (+1.50%) ▲|UNH425.67+10.04 (+2.42%) ▲|UNP278.20+6.20 (+2.28%) ▲|UPS110.08+2.58 (+2.40%) ▲|USB62.07+1.67 (+2.76%) ▲|V351.73+8.64 (+2.52%) ▲|VZ42.02-0.33 (-0.77%) ▼|WFC85.52+2.88 (+3.49%) ▲|WMT108.33-4.93 (-4.35%) ▼|XOM136.32-0.40 (-0.29%) ▼|AAPL294.09+4.73 (+1.63%) ▲|ABBV250.46-1.18 (-0.47%) ▼|ABT91.99+1.25 (+1.38%) ▲|ACN133.69+9.25 (+7.43%) ▲|ADBE211.66+6.64 (+3.24%) ▲|AMAT642.79-80.22 (-11.09%) ▼|AMD550.87-30.04 (-5.17%) ▼|AMGN358.85-3.27 (-0.90%) ▼|AMT167.08+3.51 (+2.15%) ▲|AMZN244.01+5.67 (+2.38%) ▲|AVGO369.88-7.88 (-2.08%) ▼|AXP348.36+10.11 (+2.99%) ▲|BA217.42+0.95 (+0.44%) ▲|BAC58.31+1.33 (+2.33%) ▲|BKNG184.07+5.83 (+3.27%) ▲|BLK979.29+17.73 (+1.84%) ▲|BMY56.35-1.28 (-2.21%) ▼|BNY146.80+2.19 (+1.51%) ▲|BRK-B502.27+1.88 (+0.38%) ▲|C139.73-0.24 (-0.17%) ▼|CAT995.45-69.45 (-6.52%) ▼|CL92.18+0.50 (+0.55%) ▲|CMCSA24.09-0.47 (-1.89%) ▼|COF203.87+3.25 (+1.62%) ▲|COP103.55-0.41 (-0.39%) ▼|COST925.88-9.60 (-1.03%) ▼|CRM164.60+7.94 (+5.07%) ▲|CSCO116.40-1.06 (-0.90%) ▼|CVS104.62+1.17 (+1.13%) ▲|CVX166.22+0.46 (+0.28%) ▲|DE628.68-5.65 (-0.89%) ▼|DHR193.65+3.17 (+1.66%) ▲|DIS96.53+0.28 (+0.29%) ▲|DUK125.55-1.04 (-0.82%) ▼|EMR140.56-2.60 (-1.81%) ▼|FDX315.06+1.93 (+0.62%) ▲|GD362.21+7.97 (+2.25%) ▲|GE371.57-2.16 (-0.58%) ▼|GEV1,138.85-36.01 (-3.07%) ▼|GILD126.08-0.26 (-0.21%) ▼|GM75.52-1.57 (-2.03%) ▼|GOOG356.07+2.74 (+0.77%) ▲|GOOGL359.17+1.80 (+0.50%) ▲|GS1,024.54+13.17 (+1.30%) ▲|HD353.46+0.78 (+0.22%) ▲|HON220.93-2.97 (-1.33%) ▼|IBM289.18+7.97 (+2.83%) ▲|INTC128.11-11.53 (-8.25%) ▼|INTU270.19+9.19 (+3.52%) ▲|ISRG401.91+4.23 (+1.06%) ▲|JNJ252.47-1.51 (-0.59%) ▼|JPM333.67+6.34 (+1.94%) ▲|KO81.40+0.13 (+0.15%) ▲|LIN536.36+17.42 (+3.36%) ▲|LLY1,175.64-23.79 (-1.98%) ▼|LMT517.91+8.45 (+1.66%) ▲|LOW223.14+2.65 (+1.20%) ▲|LRCX386.96-46.37 (-10.70%) ▼|MA526.21+12.61 (+2.46%) ▲|MCD271.02+0.71 (+0.26%) ▲|MDLZ58.73+0.89 (+1.53%) ▲|MDT78.92+0.69 (+0.88%) ▲|META622.54+59.25 (+10.52%) ▲|MMM160.87-1.04 (-0.64%) ▼|MO72.17+0.22 (+0.30%) ▲|MRK126.10-2.41 (-1.87%) ▼|MS211.85+2.81 (+1.34%) ▲|MSFT387.67+14.65 (+3.93%) ▲|MU1,044.93-109.37 (-9.47%) ▼|NEE86.73-1.04 (-1.18%) ▼|NFLX74.01+2.61 (+3.66%) ▲|NKE42.02+0.97 (+2.35%) ▲|NOW106.39+7.11 (+7.16%) ▲|NVDA198.75-1.35 (-0.67%) ▼|ORCL143.87-2.69 (-1.83%) ▼|PEP140.59+5.19 (+3.83%) ▲|PFE23.80-0.29 (-1.18%) ▼|PG146.10-0.54 (-0.37%) ▼|PLTR127.54+10.87 (+9.32%) ▲|PM179.59-1.32 (-0.73%) ▼|QCOM183.81-0.98 (-0.53%) ▼|RTX190.13+0.40 (+0.21%) ▲|SBUX103.42+1.23 (+1.20%) ▲|SCHW95.82+3.55 (+3.84%) ▲|SO95.23-0.48 (-0.50%) ▼|SPG221.12-2.53 (-1.13%) ▼|T20.64-0.06 (-0.28%) ▼|TMO514.97+13.61 (+2.71%) ▲|TMUS173.29+5.56 (+3.31%) ▲|TSLA426.19+5.59 (+1.33%) ▲|TXN299.13+1.06 (+0.36%) ▲|UBER73.24+1.08 (+1.50%) ▲|UNH425.67+10.04 (+2.42%) ▲|UNP278.20+6.20 (+2.28%) ▲|UPS110.08+2.58 (+2.40%) ▲|USB62.07+1.67 (+2.76%) ▲|V351.73+8.64 (+2.52%) ▲|VZ42.02-0.33 (-0.77%) ▼|WFC85.52+2.88 (+3.49%) ▲|WMT108.33-4.93 (-4.35%) ▼|XOM136.32-0.40 (-0.29%) ▼|
33.9 C
New York
Wednesday, July 1, 2026

Tag: stage

newssourceFORcompanyinformationcontent1releasesmarket

Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection

Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ("MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus (“BKPyV”)-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients (“KTR”).

Yali Capital Raises ₹893 Crores to Back India’s Deep Tech Revolution

BENGALURU, India, July 25, 2025 /PRNewswire/ -- Yali Capital, a SEBI-registered Category II Alternative Investment Fund (AIF), today announced the successful closure of its...

Troller Cat Enters Stage 14 of Presale with $400K Raised, Announces Ethereum-Based Staking Program

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- Troller Cat, a meme-inspired cryptocurrency project built on Ethereum, has officially entered Stage 14 of its 26-stage presale. With over $400,000 raised and more than 1,500 holders onboard, the project continues to gain traction amid rising demand for community-driven blockchain tokens.

Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering

NANJING, China, July 25, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the...

Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering

NANJING, China, July 24, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the...

Orla Mining Provides Initial Update on Pit Wall Event at Camino Rojo

VANCOUVER, BC, July 24, 2025 /CNW/ - Orla Mining Ltd. (TSX: OLA) (NYSE: ORLA) ("Orla" or the "Company") is providing an update on the...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

Nelnet Introduces Propelr, an Employee Learning Company Committed to Launching Workforce Potential

LINCOLN, Neb., July 24, 2025 /PRNewswire/ -- Nelnet Business Services, a division of Nelnet, Inc. (NYSE: NNI), announces the launch of a new company, Propelr,...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

Korsail Formalizes Permitting Playbook to Guide Transparent, Community-Aligned Renewable Energy Development

DENVER, July 24, 2025 /PRNewswire/ -- Korsail Energy, a leading renewable energy developer announced today the release of its newly enhanced Community Engagement Guidelines...

Algernon Announces Closing of the Private Placement Financing

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStage

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers